On 16 September 2014, a new revision of Module VI on  Management and Reporting of Adverse Reactions to Medicinal Products came into effect.

GVP Module VI has been revised to provide clarification on the clock start for reporting valid case reports and on the handling of languages in case reports. The revisions include additional guidance on reporting from post-authorisation safety studies.

Further information available here